The potential impact of antipsychotics on lipids in schizophrenia: Is there enough evidence to confirm a link?

Journal of Psychopharmacology

Volumn 19, Issue 6 SUPPL., 2005, Pages 76-83

  Bushe, Chris ^a   Paton, Carol ^b  

^a ELI LILLY AND COMPANY   (United States)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atypical antipsychotics; Dyslipidaemia; Hyperlipidaemia; Lipids; Schizophrenia; Typical antipsychotics

Indexed keywords

ANTILIPEMIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHOLESTEROL; CLOZAPINE; FIBRIC ACID DERIVATIVE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXERCISE; GENETICS; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; LIPID BLOOD LEVEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SCREENING TEST; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; LIPIDS; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33744939217     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881105058719     Document Type: Review

References (43)

1. Almeras N, Despres J P, Villeneuve J, Demers M F, Roy M A, Cadrin C, Mottard J P, Bouchard R H (2004) Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatr 65: 557-564
2. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64: 598-604
3. ATP III (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285(19): 2486-2497
4. Barak Y, Aizenberg D (2003) Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drugs Aging 20: 893-896
5. British Cardiac Society (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 80 (Suppl 2): 1-29
6. Citrome L L, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55: 1006-1013
7. Clark M, Dubowski K, Colmore J (1971). The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 11: 883-889
8. Conley R R (2004) Metabolic risk associated with second-generation antipsychotic treatment; results from a double blind randomised 8 week trial of risperidone and olanzapine. Poster presented at the ACNP, Puerto Rica, December
9. Durrington P (2003) Dyslipidaemia. Lancet 362: 717-731
10. Ford E S, Mokdad A H, Giles W H, Mensah G A (2003) Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 107: 2185-2189
11. Garyfallos G, Dimelis D, Kouniakis P, Sidiropoulos N, Karastergiou A,., (2003) Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry 18(6): 320-321
12. Ghaeli P, Dufresne R L (1996) Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 53: 2079-2081
13. Gupta S, Masand P S, Virk S, Schwartz T, Hameed A, Frank B L, Lockwood K (2004) Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 70: 57-62
14. Hardy T, Sowell M O, Marquez E, Cavazzoni P, Taylor C C, Breier A (2003) Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychotics. Eur Neuropsychopharmacol 13 (Suppl 4): S339-S340
15. Kingsbury S J, Fayek M, Trufasiu D, Zada J, Simpson G M (2001) The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62: 347-349
16. Kinon B J, Basson B R, Gilmore J A, Tollefson G D (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62: 92-100
17. Kinon B J, Liu H, Ahl J, Baker R W (2003) Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, four-month study. Schizophr Res 60 (1 Suppl): 358
18. Kohen D, (2004). Diabetes Mellitus and schizophrenia: historical perspective. British J Psychiatry; 184 (Suppl 47): S64-66
19. Koro C E, Fedder D O, L'Italien G J, Weiss S, Magder L S, Kreyenbuhl J, Revicki D, Buchanan R W (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59: 1021-1026
20. Lambert B L, Chang K Y, Tafasse E, Carson W (2005) Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. Journal of Clinical Psychopharmacology 25: 12-18
21. Lindenmayer J P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J P, Cooper T B, Chakos M, Lieberman J A (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290-296
22. Lund B C, Perry P J, Brooks J M, Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry 58: 1172-1176
23. McCreadie R G, Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br J Psychiatry 2003; 183: 534-539
24. McQuade R D, Stock E, Marcus R, Jody D, Gharbia N A, Vanveggel S, Archibald D, Carson W H (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65 (Suppl 18): 47-56
25. Martinez J A, Velasco J J, Urbistondo D (1994) Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalised psychiatric patients. Journal of the American College of Nutrition 13: 192-197
26. Melkersson K I, Dahl M L (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170: 157-166
27. Melkersson K I, Hulting A L, Brismar K E (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749
28. Meyer J M (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63: 425-433
29. Meyer J M, Koro C E (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70(1): 1-17
30. Mokdad A H, Bowman B A, Ford E S, Vinicor F, Marks J S, Koplan J P (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195-1200
31. Osser D N, Najarian D M, Dufresne R L (1999) Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 60: 767-770
32. Paton C, Esop R, Young C, Taylor D (2004) Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 110: 299-305
33. Quetiapine. USA Summary of Product Characteristics
34. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S (2004) Hyperlipidaemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 65: 547-550
35. Shafique M, Khan I A, Akhtar M H, Hussain I (1988) Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers. J Pak Med Assoc 38: 259-261
36. Sheitman B B, Bird P M, Binz W, Akinli L, Sanchez C (1999) Olanzapine induced elevation of plasma triglyceride levels. Am J Psych 156: 1471-1472
37. Smith R C, Lindenmayer J P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005a) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 8: 183-194
38. Smith R, Lindenmayer J P, Buga A, Mautue M, Vaidhyanathaswamy S, Butler E (2005b) Metabolic changes during 6 months treatment with olanzapine or risperidone: Preliminary results from randomized trial. Schizophrenia Bulletin 31(2): S570
39. Sramek J J, Cutler N R, Shiovitz T (2003) The effect of antipsychotics on plasma lipids. J Clin Psychopharmacol 23: 679-680
40. Stroup T S (2004) Antipsychotic drug treatment of schizophrenia: update on the CATIE trial. In: NCDEU Abstracts from the 44th Annual Meeting, June 1-4, 2004, Phoenix, Arizona. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health, Bethesda, MD
41. Stroup T S, McEvoy J P, Swartz M S, Byerly M J, Glick I D, Canive J M, McGee M F, Simpson G M, Stevens M C, Lieberman J A (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29: 15-31
42. Taylor D, Young C, Esop R, Paton C, Walwyn R (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185: 152-156
43. Wirshing D A, Boyd J A, Meng L R, Ballon J S, Marder S R, Wirshing W C (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63: 856-865